Seattle Genetics Inc (SGEN)

62.73
NASDAQ : Health Care
Prev Close 63.07
Day Low/High 61.50 / 63.22
52 Wk Low/High 29.52 / 75.36
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 142.49M
Market Cap 8.99B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

Activist Investor to Block Partnership of Immunomedics and Seattle Genetics

The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics

VenBio accuses Immunomedics management of undervaluing and essentially giving away the cancer drug IMMU-132 because they were afraid of losing their jobs in a proxy vote.

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

SGEN SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Seattle Genetics Inc. And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics To Present At Leerink Partners 6th Annual Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Immunomedics Announces Postponement Of 2016 Annual Meeting

Immunomedics Announces Postponement Of 2016 Annual Meeting

New Meeting Date Provides Time for Modified "Go-Shop" Period Negotiated in Global Licensing Agreement of IMMU-132 with Seattle Genetics to Have Expired or Otherwise Been Completed and Allows Stockholders to Carefully Consider the Significant Value Created by the Licensing Transaction

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics For Sacituzumab Govitecan (IMMU-132) With Potential Payments Of Up To Approximately $2 Billion, Plus Royalties

Immunomedics to Receive $250 Million in Upfront Cash Payment; Plus Among Other Milestone Payments, an Additional $50 Million or Negotiated Economic Splits Relating to Rights Outside US, Canada and EU

Seattle Genetics Announces Global License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132), A Promising Late-Stage ADC For Solid Tumors

Seattle Genetics Announces Global License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132), A Promising Late-Stage ADC For Solid Tumors

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc.

Seattle Genetics Reports Fourth Quarter And Year 2016 Financial Results

Seattle Genetics Reports Fourth Quarter And Year 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN), a global biotechnology company, today reported financial results for the fourth quarter and year ended December 31, 2016.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Seattle Genetics, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Seattle Genetics, Inc. Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Seattle Genetics, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Seattle Genetics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Western District of Washington on behalf...

SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

SGEN INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc.

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2016 Financial Results On February 9, 2017

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2016 Financial Results On February 9, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets.

SGEN LOSS NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors Of Important Deadline In Class Action

SGEN LOSS NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Seattle Genetics Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Seattle Genetics Inc. - SGEN

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Seattle Genetics Inc. - SGEN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Seattle Genetics Inc.

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today announced enrollment of the first patient in a multicenter phase 1 clinical trial of SGN-CD352A for patients with relapsed or refractory...

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Seattle Genetics, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Seattle Genetics, Inc. - SGEN

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Seattle Genetics, Inc. - SGEN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Seattle Genetics, Inc.